The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis
Abstract
The development of clinical symptoms in multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE) involves T‐cell activation and migration into the central nervous system, production of glial‐derived inflammatory molecules, and demyelination and axonal damage. Ligands of the peroxisome proliferator‐activated receptor (PPAR) exert anti‐inflammatory effects on glial cells, reduce proliferation and activation of T cells, and induce myelin gene expression. We demonstrate in two models of EAE that orally administered PPARγ ligand pioglitazone reduced the incidence and severity of monophasic, chronic disease in C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein peptide and of relapsing disease in B10.Pl mice immunized with myelin basic protein. Pioglitazone also reduced clinical signs when it was provided after disease onset. Clinical symptoms were reduced by two other PPARγ agonists, suggesting a role for PPARγ activation in protective effects. The suppression of clinical signs was paralleled by decreased lymphocyte infiltration, lessened demyelination, reduced chemokine and cytokine expression, and increased inhibitor of kappa B (IkB) expression in the brain. Pioglitazone also reduced the antigen‐dependent interferon‐γ production from EAE‐derived T cells. These results suggest that orally administered PPARγ agonists could provide therapeutic benefit in demyelinating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedLehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 4×
“E-mail: dlfeins@uic.edu 694 © 2002 Wiley-Liss, Inc. such as troglitazone, pioglitazone (PIO), and rosiglitazone,15 and tyrosine-based agonists such as GW347845.”
BackgroundInfluentialRegulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Su, C. G., Wen, X., Bailey, S. T., Jiang, W., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., & Wu, G. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7145 · Cited by 767
Lemberger, T., Desvergne, B., & Wahli, W. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.335 · Cited by 712
Cited by
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Self-citationRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Moreno, S., Farioli-Vecchioli, S., & Cerù, M. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 587
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Maalouf, M., Rho, J. M., & Mattson, M. P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.002 · Cited by 574
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Self-citationMitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
Combinatorial roles of nuclear receptors in inflammation and immunity
Glass, C. K., & Ogawa, S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1748 · Cited by 464
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“In line with these findings, recent studies have documented the salutary effects of PPARcagonists in animal models of multiple sclerosis (Feinstein et al. 2002a; Niino et al. 2001; Diab et al. 2004; Natarajan and Bright 2002) and Parkinson’s disease (Dehmer et al. 2004; Breidert et al. 2002) and…”
BackgroundResultSelf-citationWelch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., & Glass, C. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031789100 · Cited by 429
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
Self-citationDehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., & Schulz, J. B. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382
Self-citationKlotz, L., Burgdorf, S., Dani, I., Saijo, K., Flossdorf, J., Hucke, S., Alferink, J., Novak, N., Beyer, M., Mayer, G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082771 · Cited by 354
Modulation of Macrophage Efferocytosis in Inflammation
Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M., & Bratton, D. L. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00057 · Cited by 349
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Self-citationMolecular Control of Oligodendrocyte Development
Elbaz, B., & Popko, B. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.01.002 · Cited by 293
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Self-citationPPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
Bordet, R., Ouk, T., Petrault, O., Gelé, P., Gautier, S., Laprais, M., Deplanque, D., Duriez, P., Staels, B., Fruchart, J. C., et al. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341341 · Cited by 273
Sundararajan, S., Gamboa, J. L., Victor, N. A., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Self-citationPPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
Corona, J. C., & Duchen, M. R. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.023 · Cited by 259
Negrotto, L., Farez, M. F., & Correale, J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4807 · Cited by 198
Storer, P. D., Xu, J., Chavis, J., & Drew, P. D. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.12.015 · Cited by 154
Zhang-Gandhi, C. X., & Drew, P. D. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.007 · Cited by 117
Dello Russo, C., Lisi, L., Feinstein, D. L., & Navarra, P. (2013) · Glia · doi:10.1002/glia.22433 · Cited by 96
“The disease tends to remain stable or progress over the time; in fact, animals barely recover unless effectively treated (Feinstein et al., 2002). mTOR INHIBITORS AND NEUROPROTECTION IN EAE The ability of mTOR inhibition to prevent CD41 effector T cell differentiation and promote the generation of…”
BackgroundSelf-citationMolecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Self-citationRodríguez-Pascau, L., Vilalta, A., Cerrada, M., Traver, E., Forss-Petter, S., Weinhofer, I., Bauer, J., Kemp, S., Pina, G., Pascual, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0555 · Cited by 40
Metadata
- Authors
- Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-05-21
- Volume
- 51
- Issue
- 6
- Pages
- 694-702
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2144473903
- Cited by
- 294
- References
- 42
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.